HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA's Former CFO Alleges Improper Expenses By Fabricant, Religious And Gender Harassment

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

CEO Daniel Fabricant and the NPA board's president say former CFO Brent Weickert's allegations in a complaint filed in California state court are baseless. Weickert, with NPA from 1997 until October, says he was dismissed after he stated his concerns to NPA's board and to Fabricant.

You may also be interested in...



Trade Groups Dismiss Jarrow’s Criticism Of FDA’s Fabricant

Dietary supplement industry trade groups disavow statements by Jarrow Formulas’ president that cast as industry consensus his criticism of Daniel Fabricant’s work as FDA’s top supplement program official.

Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing

Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.

US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs

FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS123061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel